Clinica Chimica Acta最新文献_第10页

Enhancing creatinine detection: Innovative biosensors for monitoring kidney function 增强肌酐检测：用于监测肾功能的创新生物传感器。

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2026-02-15 Epub Date: 2025-12-15 DOI: 10.1016/j.cca.2025.120789

Mohammad Mahdi Heidari , Sepideh Shadravan , Samira Jafarisis , Shahab Masoumi , Shahla Shiri , Sajjad Jafarzadeh , Ahmad Mobed

Creatinine is a waste product generated from muscle metabolism, and its levels in the blood and urine serve as key indicators of renal function. Fast and sensitive detection of creatinine is crucial for early diagnosis, monitoring disease progression, and guiding treatment decisions. Recent advancements in nanomaterials have led to the development of innovative biosensors for creatinine monitoring, providing a transformative approach to kidney disease diagnostics. This paper explores the potential of nanomaterial-based biosensors to enhance sensitivity, specificity, and rapid response times in detecting creatinine levels, a critical biomarker for kidney function assessment. We review various nanomaterials, including carbon-based nanostructures, metal nanoparticles, and quantum dots, highlighting their unique electrochemical properties and biocompatibility. These materials exhibit enhanced surface area and reactivity, contributing to improved sensitivity and specificity, thus enabling the identification of lower concentrations of creatinine while minimizing interference from other substances. Furthermore, we discuss the integration of these biosensors into wearable technologies to facilitate continuous monitoring, making early detection of kidney issues more accessible. This advancement empowers patients to monitor their health in real-time while generating valuable data for personalized medicine strategies. Our findings indicate that these novel biosensing platforms not only improve diagnostic accuracy but also play a crucial role in reducing the burden of chronic kidney diseases. In addition, implementing these biosensors could significantly streamline the diagnostic process, allowing for timely interventions. Ultimately, our study underscores the crucial role of innovative biosensing technologies in enhancing renal health management.

肌酐是肌肉代谢产生的废物，其在血液和尿液中的水平是肾功能的关键指标。快速、灵敏地检测肌酐对于早期诊断、监测疾病进展和指导治疗决策至关重要。纳米材料的最新进展导致了用于肌酐监测的创新生物传感器的发展，为肾脏疾病诊断提供了一种变革性的方法。本文探讨了基于纳米材料的生物传感器的潜力，以提高检测肌酐水平的敏感性、特异性和快速反应时间，肌酐水平是肾功能评估的关键生物标志物。我们回顾了各种纳米材料，包括碳基纳米结构、金属纳米粒子和量子点，重点介绍了它们独特的电化学性能和生物相容性。这些材料表现出增强的表面积和反应性，有助于提高灵敏度和特异性，从而能够识别较低浓度的肌酐，同时最大限度地减少其他物质的干扰。此外，我们讨论了将这些生物传感器集成到可穿戴技术中，以促进持续监测，使肾脏问题的早期检测更容易实现。这一进步使患者能够实时监控自己的健康状况，同时为个性化医疗策略生成有价值的数据。我们的研究结果表明，这些新的生物传感平台不仅提高了诊断准确性，而且在减轻慢性肾脏疾病的负担方面发挥了至关重要的作用。此外，实施这些生物传感器可以大大简化诊断过程，允许及时干预。最后，我们的研究强调了创新生物传感技术在加强肾脏健康管理中的关键作用。

{"title":"Enhancing creatinine detection: Innovative biosensors for monitoring kidney function","authors":"Mohammad Mahdi Heidari , Sepideh Shadravan , Samira Jafarisis , Shahab Masoumi , Shahla Shiri , Sajjad Jafarzadeh , Ahmad Mobed","doi":"10.1016/j.cca.2025.120789","DOIUrl":"10.1016/j.cca.2025.120789","url":null,"abstract":"<div><div>Creatinine is a waste product generated from muscle metabolism, and its levels in the blood and urine serve as key indicators of renal function. Fast and sensitive detection of creatinine is crucial for early diagnosis, monitoring disease progression, and guiding treatment decisions. Recent advancements in nanomaterials have led to the development of innovative biosensors for creatinine monitoring, providing a transformative approach to kidney disease diagnostics. This paper explores the potential of nanomaterial-based biosensors to enhance sensitivity, specificity, and rapid response times in detecting creatinine levels, a critical biomarker for kidney function assessment. We review various nanomaterials, including carbon-based nanostructures, metal nanoparticles, and quantum dots, highlighting their unique electrochemical properties and biocompatibility. These materials exhibit enhanced surface area and reactivity, contributing to improved sensitivity and specificity, thus enabling the identification of lower concentrations of creatinine while minimizing interference from other substances. Furthermore, we discuss the integration of these biosensors into wearable technologies to facilitate continuous monitoring, making early detection of kidney issues more accessible. This advancement empowers patients to monitor their health in real-time while generating valuable data for personalized medicine strategies. Our findings indicate that these novel biosensing platforms not only improve diagnostic accuracy but also play a crucial role in reducing the burden of chronic kidney diseases. In addition, implementing these biosensors could significantly streamline the diagnostic process, allowing for timely interventions. Ultimately, our study underscores the crucial role of innovative biosensing technologies in enhancing renal health management.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"582 ","pages":"Article 120789"},"PeriodicalIF":2.9,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changing in blood cells for infection detection: “Monocyte distribution width” acts as a key determinant in differentiating localized and blood stream infections 检测感染时血细胞的变化：“单核细胞分布宽度”是区分局部感染和血流感染的关键决定因素。

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2026-02-15 Epub Date: 2026-01-05 DOI: 10.1016/j.cca.2026.120819

Agostino Ognibene , Maria Lorubbio , Sara Montemerani , Giulio Camarlinghi , Tommaso Novi , Claudia Artini , Eva Maria Parisio , Raffaella Pavani , Danilo Tacconi , Maurizio Zanobetti

Background

Early identification of bloodstream infections (BSI) in the Emergency Department (ED) remains a clinical challenge. Monocyte Distribution Width (MDW), a novel biomarker available from the complete blood count, was prospectively evaluated for its diagnostic and prognostic utility in patients with suspected infection.

Methods

We conducted a prospective, observational cohort study enrolling 608 adult ED patients. Following a comprehensive diagnostic workup, patients were retrospectively adjudicated into three primary groups: No Infection (n = 196), Localized Infection (n = 235), and Bloodstream Infection (BSI) (n = 134). The diagnostic accuracy of MDW was compared to procalcitonin (PCT) and C-reactive protein (CRP) using receiver operating characteristic (ROC) analysis.

Results

In this cohort, MDW demonstrated high accuracy for BSI detection (Area Under the Curve [AUC] = 0.936), representing a statistically significant improvement over both PCT (AUC = 0.818; p < 0.0001) and CRP (AUC = 0.829; p < 0.0001). It also showed good accuracy in discriminating localized infections from the no-infection group (AUC = 0.748). Notably, among the biomarkers tested, MDW was the only biomarker significantly elevated in non-survivors compared to survivors (p = 0.001), indicating a unique prognostic value for in-hospital mortality.

Conclusions

In ED patients with suspected infection, MDW is a highly effective biomarker for the early detetion of BSI, demonstrating significantly higher diagnostic accuracy than PCT and CRP in this study. Its ability to help stratify patients with localized versus systemic infection and to predict mortality makes it a valuable tool for early risk assessment and clinical decision-making.

背景：早期识别血流感染（BSI）在急诊科（ED）仍然是一个临床挑战。单核细胞分布宽度（MDW）是一种从全血细胞计数中获得的新型生物标志物，对其在疑似感染患者中的诊断和预后效用进行了前瞻性评估。方法：我们进行了一项前瞻性、观察性队列研究，纳入608例成人ED患者。经过全面的诊断检查，回顾性地将患者分为三个主要组：无感染（n = 196），局部感染（n = 235）和血液感染（n = 134）。采用受试者工作特征（ROC）分析，比较MDW与降钙素原（PCT）和c反应蛋白（CRP）的诊断准确性。结果：在本研究中，MDW对BSI的检测准确率较高（曲线下面积[AUC] = 0.936），较两种PCT （AUC = 0.818;p ）有统计学意义的提高。结论：在疑似感染的ED患者中，MDW是一种非常有效的早期检测BSI的生物标志物，在本研究中，MDW的诊断准确率明显高于PCT和CRP。它能够帮助对局部感染和全身性感染患者进行分层，并预测死亡率，使其成为早期风险评估和临床决策的宝贵工具。

{"title":"Changing in blood cells for infection detection: “Monocyte distribution width” acts as a key determinant in differentiating localized and blood stream infections","authors":"Agostino Ognibene , Maria Lorubbio , Sara Montemerani , Giulio Camarlinghi , Tommaso Novi , Claudia Artini , Eva Maria Parisio , Raffaella Pavani , Danilo Tacconi , Maurizio Zanobetti","doi":"10.1016/j.cca.2026.120819","DOIUrl":"10.1016/j.cca.2026.120819","url":null,"abstract":"<div><h3>Background</h3><div>Early identification of bloodstream infections (BSI) in the Emergency Department (ED) remains a clinical challenge. Monocyte Distribution Width (MDW), a novel biomarker available from the complete blood count, was prospectively evaluated for its diagnostic and prognostic utility in patients with suspected infection.</div></div><div><h3>Methods</h3><div>We conducted a prospective, observational cohort study enrolling 608 adult ED patients. Following a comprehensive diagnostic workup, patients were retrospectively adjudicated into three primary groups: No Infection (n = 196), Localized Infection (n = 235), and Bloodstream Infection (BSI) (n = 134). The diagnostic accuracy of MDW was compared to procalcitonin (PCT) and C-reactive protein (CRP) using receiver operating characteristic (ROC) analysis.</div></div><div><h3>Results</h3><div>In this cohort, MDW demonstrated high accuracy for BSI detection (Area Under the Curve [AUC] = 0.936), representing a statistically significant improvement over both PCT (AUC = 0.818; p < 0.0001) and CRP (AUC = 0.829; p < 0.0001). It also showed good accuracy in discriminating localized infections from the no-infection group (AUC = 0.748). Notably, among the biomarkers tested, MDW was the only biomarker significantly elevated in non-survivors compared to survivors (p = 0.001), indicating a unique prognostic value for in-hospital mortality.</div></div><div><h3>Conclusions</h3><div>In ED patients with suspected infection, MDW is a highly effecti<em>ve biomarker for the early dete</em>tion of BSI, demonstrating significantly higher diagnostic accuracy than PCT and CRP in this study. Its ability to help stratify patients with localized versus systemic infection and to predict mortality makes it a valuable tool for early risk assessment and clinical decision-making.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"582 ","pages":"Article 120819"},"PeriodicalIF":2.9,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating molecular diagnostics and artificial intelligence in chronic microbial disease 整合分子诊断和人工智能在慢性微生物疾病中的应用。

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2026-02-15 Epub Date: 2025-12-26 DOI: 10.1016/j.cca.2025.120803

Bandita Dutta, Rina Ray Ray

Chronic microbial diseases, often driven by biofilm formation, pose a persistent global health burden due to their complex diagnosis, resistance mechanisms, and prolonged disease courses. Conventional diagnostic methods are time-consuming and often insufficient for early, precise detection and prognosis. Recent advances in molecular diagnostics, including PCR, hybridization, next-generation sequencing, and CRISPR-based assays, have enabled rapid, non-invasive, and highly sensitive detection of pathogens and resistance markers. Complementary “omics” technologies, like genomics, proteomics, and metabolomics, provide deeper insights into disease pathways, aiding in personalized treatment strategies. Furthermore, the integration of artificial intelligence (AI) and big data analytics enhances the interpretation of complex molecular datasets, enabling pattern recognition, risk prediction, and tailored therapeutic decisions. This manuscript reviews current tools and emerging technologies for the diagnosis and prognosis of chronic microbial diseases, highlighting the transformative potential of AI-driven precision medicine to improve patient outcomes through early detection, individualized treatment, and better disease management.

慢性微生物疾病通常由生物膜形成驱动，由于其复杂的诊断、耐药机制和延长的病程，造成了持续的全球健康负担。传统的诊断方法耗时长，而且往往不足以进行早期、精确的检测和预后。分子诊断的最新进展，包括PCR、杂交、下一代测序和基于crispr的检测，已经能够快速、无创和高度敏感地检测病原体和耐药性标记。互补的“组学”技术，如基因组学、蛋白质组学和代谢组学，提供了对疾病途径的更深入了解，有助于个性化治疗策略。此外，人工智能（AI）和大数据分析的集成增强了对复杂分子数据集的解释，实现了模式识别、风险预测和量身定制的治疗决策。本文回顾了目前用于慢性微生物疾病诊断和预后的工具和新兴技术，强调了人工智能驱动的精准医疗的变革潜力，通过早期发现、个性化治疗和更好的疾病管理来改善患者的预后。

{"title":"Integrating molecular diagnostics and artificial intelligence in chronic microbial disease","authors":"Bandita Dutta, Rina Ray Ray","doi":"10.1016/j.cca.2025.120803","DOIUrl":"10.1016/j.cca.2025.120803","url":null,"abstract":"<div><div>Chronic microbial diseases, often driven by biofilm formation, pose a persistent global health burden due to their complex diagnosis, resistance mechanisms, and prolonged disease courses. Conventional diagnostic methods are time-consuming and often insufficient for early, precise detection and prognosis. Recent advances in molecular diagnostics, including PCR, hybridization, next-generation sequencing, and CRISPR-based assays, have enabled rapid, non-invasive, and highly sensitive detection of pathogens and resistance markers. Complementary “omics” technologies, like genomics, proteomics, and metabolomics, provide deeper insights into disease pathways, aiding in personalized treatment strategies. Furthermore, the integration of artificial intelligence (AI) and big data analytics enhances the interpretation of complex molecular datasets, enabling pattern recognition, risk prediction, and tailored therapeutic decisions. This manuscript reviews current tools and emerging technologies for the diagnosis and prognosis of chronic microbial diseases, highlighting the transformative potential of AI-driven precision medicine to improve patient outcomes through early detection, individualized treatment, and better disease management.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"582 ","pages":"Article 120803"},"PeriodicalIF":2.9,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating the diagnostic significance of serum NRCAM in small cell lung cancer 探讨血清NRCAM对小细胞肺癌的诊断意义。

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2026-02-15 Epub Date: 2026-01-06 DOI: 10.1016/j.cca.2025.120815

Yinyi Chen , Kexin Han , Liping Wei , Xinlu Sun , Yanzhao Liu , Qunxia Wang , Yang Wu , Simei Chen , Jianlin Yu , Yi Luo , Lili Wen , Liming Tan

Objective

This study aims to investigate the clinical significance of serum neuronal cell adhesion molecule (NRCAM) in small cell lung cancer (SCLC) diagnosis.

Methods

Serum NRCAM levels were measured using enzyme-linked immunosorbent assay in 80 SCLC patients, 98 patients with non-small cell lung cancer (NSCLC), 73 patients with pulmonary nodules (PN) and 56 healthy controls. Neuron specific enolase (NSE) and progastrin-releasing peptide (ProGRP) expression were detected using chemiluminescence immunoassay.

Results

(1) Significant differences were detected in serum NRCAM, NSE and ProGRP levels among the groups (P < 0.05), with the highest levels observed in SCLC patients. (2) Correlation assessment revealed that serum NRCAM concentrations were positively correlated with smoking (r = 0.39) and lymph node metastasis (r = 0.37) (both P < 0.01). (3) NRCAM concentration was positively correlated with the clinical stage of SCLC, being significantly lower in stages I-II compared to stages III-IV (P < 0.01), and was remarkably lower in the non-metastatic group of SCLC relative to the metastatic group (P < 0.01). (4) Compared to the NSCLC group, ProGRP exhibited the largest area under the receiver operating characteristic curve (AUC) and the highest sensitivity for SCLC diagnosis, with values of 0.86 and 76 %, respectively. NRCAM had the highest specificity for SCLC diagnosis (94 %). Compared to the PN group, NRCAM exhibited a larger AUC (0.81) and higher sensitivity (74 %) for SCLC diagnosis. Conversely, NSE displayed a higher specificity for SCLC diagnosis (93 %). The combined diagnostic approach using NRCAM, NSE, and ProGRP yielded the largest AUC and the highest sensitivity, at 0.94 and 91 %, respectively. (5) Binary logistic regression analysis revealed that smoking and lymph node metastasis were potential risk factors influencing serum NRCAM levels.

Conclusions

NRCAM possess significant potential for diagnosing SCLC and distinguishing SCLC from NSCLC and PN. Moreover, the combination detection of NRCAM, NSE, and ProGRP may enhance diagnostic performance, offering a novel clinical strategy for SCLC.

目的：探讨血清神经细胞粘附分子（NRCAM）在小细胞肺癌（SCLC）诊断中的临床意义。方法：采用酶联免疫吸附法测定80例SCLC患者、98例非小细胞肺癌（NSCLC）患者、73例肺结节（PN）患者和56例健康对照者血清NRCAM水平。采用化学发光免疫分析法检测神经元特异性烯醇化酶（NSE）和原胃泌素释放肽（ProGRP）的表达。结果：(1)各组患者血清NRCAM、NSE、ProGRP水平差异有统计学意义（P ）结论：NRCAM对SCLC的诊断、SCLC与NSCLC、PN的鉴别具有重要意义。此外，NRCAM、NSE和ProGRP联合检测可提高SCLC的诊断效果，为SCLC的临床诊断提供了一种新的策略。

{"title":"Investigating the diagnostic significance of serum NRCAM in small cell lung cancer","authors":"Yinyi Chen , Kexin Han , Liping Wei , Xinlu Sun , Yanzhao Liu , Qunxia Wang , Yang Wu , Simei Chen , Jianlin Yu , Yi Luo , Lili Wen , Liming Tan","doi":"10.1016/j.cca.2025.120815","DOIUrl":"10.1016/j.cca.2025.120815","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to investigate the clinical significance of serum neuronal cell adhesion molecule (NRCAM) in small cell lung cancer (SCLC) diagnosis.</div></div><div><h3>Methods</h3><div>Serum NRCAM levels were measured using enzyme-linked immunosorbent assay in 80 SCLC patients, 98 patients with non-small cell lung cancer (NSCLC), 73 patients with pulmonary nodules (PN) and 56 healthy controls. Neuron specific enolase (NSE) and progastrin-releasing peptide (ProGRP) expression were detected using chemiluminescence immunoassay.</div></div><div><h3>Results</h3><div>(1) Significant differences were detected in serum NRCAM, NSE and ProGRP levels among the groups (<em>P</em> < 0.05), with the highest levels observed in SCLC patients. (2) Correlation assessment revealed that serum NRCAM concentrations were positively correlated with smoking (<em>r</em> = 0.39) and lymph node metastasis (<em>r</em> = 0.37) (both <em>P</em> < 0.01). (3) NRCAM concentration was positively correlated with the clinical stage of SCLC, being significantly lower in stages I-II compared to stages III-IV (<em>P</em> < 0.01), and was remarkably lower in the non-metastatic group of SCLC relative to the metastatic group (<em>P</em> < 0.01). (4) Compared to the NSCLC group, ProGRP exhibited the largest area under the receiver operating characteristic curve (AUC) and the highest sensitivity for SCLC diagnosis, with values of 0.86 and 76 %, respectively. NRCAM had the highest specificity for SCLC diagnosis (94 %). Compared to the PN group, NRCAM exhibited a larger AUC (0.81) and higher sensitivity (74 %) for SCLC diagnosis. Conversely, NSE displayed a higher specificity for SCLC diagnosis (93 %). The combined diagnostic approach using NRCAM, NSE, and ProGRP yielded the largest AUC and the highest sensitivity, at 0.94 and 91 %, respectively. (5) Binary logistic regression analysis revealed that smoking and lymph node metastasis were potential risk factors influencing serum NRCAM levels.</div></div><div><h3>Conclusions</h3><div>NRCAM possess significant potential for diagnosing SCLC and distinguishing SCLC from NSCLC and PN. Moreover, the combination detection of NRCAM, NSE, and ProGRP may enhance diagnostic performance, offering a novel clinical strategy for SCLC.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"582 ","pages":"Article 120815"},"PeriodicalIF":2.9,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myeloperoxidase as a Biomarker in COPD 髓过氧化物酶作为COPD的生物标志物。

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2026-02-15 Epub Date: 2025-12-19 DOI: 10.1016/j.cca.2025.120799

A. Rekha , Gaurav Gupta , Pareshkumar N. Patel , Shefali , G. PadmaPriya , Laxmidhar Maharana , Moayad Al Shahwan , Popat S. Kumbhar , Keshav Raj Paudel , Kavita Goyal , Sachin Kumar Singh , Kamal Dua

This is a critical review of the myeloperoxidase (MPO) biomarker in chronic obstructive pulmonary disease (COPD), covering its biological potential, methodology of analysis, and clinical use. Chronic inflammation and oxidative stress mediated by neutrophils are critical processes in COPD, wherein MPO, a heme peroxidase derived from neutrophils, functions as an effector and potentially as a biomarker. Patients with COPD and smokers have a high concentration of MPO in their biological compartments, which correlates with neutrophilic load, oxidative injury, and airflow obstruction. Analytical investigations have shown that it is possible to measure MPO levels in serum, plasma, sputum, and exhaled breath condensate (EBC). Nonetheless, there is significant preanalytical variability, particularly concerning the distinction between serum and plasma. Serum MPO levels are often elevated due to ex vivo neutrophil degranulation during the clotting process, suggesting that plasma may provide a more accurate measure of circulating MPO levels. While MPO shows promise, particularly when integrated into multi-marker panels for inflammatory endotyping and risk stratification, its clinical application remains limited due to the lack of standardized assays and inter-study harmonization of results. This review summarizes the existing evidence of MPO as a biomarker of neutrophil-mediated COPD inflammation, and it can be noted that although biologically plausible, it requires further rigorous standardization and validation of specific matrices (plasma vs. serum) and inclusion into compound biomarker approaches to be translated into clinics.

本文综述了髓过氧化物酶（MPO）在慢性阻塞性肺疾病（COPD）中的生物标志物，包括其生物学潜力、分析方法和临床应用。中性粒细胞介导的慢性炎症和氧化应激是COPD的关键过程，其中MPO，一种源自中性粒细胞的血红素过氧化物酶，作为一种效应物和潜在的生物标志物发挥作用。COPD患者和吸烟者的生物室中MPO浓度较高，这与中性粒细胞负荷、氧化损伤和气流阻塞有关。分析研究表明，可以测量血清、血浆、痰液和呼出冷凝水（EBC）中的MPO水平。尽管如此，在分析前仍存在显著的可变性，特别是在血清和血浆的区分方面。在凝血过程中，由于体外中性粒细胞脱粒，血清MPO水平经常升高，这表明血浆可能提供更准确的循环MPO水平测量。虽然MPO显示出了希望，特别是当与炎症内分型和风险分层的多标记面板结合时，由于缺乏标准化的分析和研究间结果的协调，其临床应用仍然受到限制。本综述总结了MPO作为中性粒细胞介导的COPD炎症的生物标志物的现有证据，并且可以注意到，尽管生物学上是合理的，但它需要进一步严格的标准化和特定基质（血浆与血清）的验证，并纳入复合生物标志物方法以转化为临床。

{"title":"Myeloperoxidase as a Biomarker in COPD","authors":"A. Rekha , Gaurav Gupta , Pareshkumar N. Patel , Shefali , G. PadmaPriya , Laxmidhar Maharana , Moayad Al Shahwan , Popat S. Kumbhar , Keshav Raj Paudel , Kavita Goyal , Sachin Kumar Singh , Kamal Dua","doi":"10.1016/j.cca.2025.120799","DOIUrl":"10.1016/j.cca.2025.120799","url":null,"abstract":"<div><div>This is a critical review of the myeloperoxidase (MPO) biomarker in chronic obstructive pulmonary disease (COPD), covering its biological potential, methodology of analysis, and clinical use. Chronic inflammation and oxidative stress mediated by neutrophils are critical processes in COPD, wherein MPO, a heme peroxidase derived from neutrophils, functions as an effector and potentially as a biomarker. Patients with COPD and smokers have a high concentration of MPO in their biological compartments, which correlates with neutrophilic load, oxidative injury, and airflow obstruction. Analytical investigations have shown that it is possible to measure MPO levels in serum, plasma, sputum, and exhaled breath condensate (EBC). Nonetheless, there is significant preanalytical variability, particularly concerning the distinction between serum and plasma. Serum MPO levels are often elevated due to ex vivo neutrophil degranulation during the clotting process, suggesting that plasma may provide a more accurate measure of circulating MPO levels. While MPO shows promise, particularly when integrated into multi-marker panels for inflammatory endotyping and risk stratification, its clinical application remains limited due to the lack of standardized assays and inter-study harmonization of results. This review summarizes the existing evidence of MPO as a biomarker of neutrophil-mediated COPD inflammation, and it can be noted that although biologically plausible, it requires further rigorous standardization and validation of specific matrices (plasma vs. serum) and inclusion into compound biomarker approaches to be translated into clinics.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"582 ","pages":"Article 120799"},"PeriodicalIF":2.9,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in the early detection of ovarian cancer 卵巢癌早期检测的最新进展。

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2026-02-15 Epub Date: 2025-12-19 DOI: 10.1016/j.cca.2025.120797

Anahita Soleimani , Akbar Amirfiroozy , Mohammad M. Pourseif , Mahmoud Shekari Khaniani

Ovarian cancer (OC), predominantly epithelial OC, remains the most lethal gynecological malignancy. Owing to its often asymptomatic or non-specific clinical presentation, approximately 70 % of patients are diagnosed at advanced stages (FIGO III–IV), typically characterized by extensive peritoneal dissemination. Although early detection is critical for improving survival outcomes, current standard diagnostic modalities, including serum CA125 and transvaginal ultrasound, lack sufficient sensitivity and specificity for population-level screening of early-stage disease. This review comprehensively evaluates emerging biomarkers and advanced diagnostic technologies, with a particular focus on liquid biopsy analytes, including circulating tumor DNA, microRNAs, and uterine liquid biopsies. We further discuss the clinical utility of multi-biomarker panels and artificial intelligence (AI)-driven models that integrate genomic, proteomic, and radiomic data, while highlighting their current performance limitations and stage-dependent diagnostic accuracy. Despite the considerable potential of liquid biopsies and AI-based approaches, challenges related to assay standardization and the need for large-scale prospective validation remain major barriers to widespread clinical implementation. Overall, this review underscores the need for robust, multimodal diagnostic strategies that may enable earlier detection and ultimately reduce OC-associated mortality.

卵巢癌（OC），主要是上皮性卵巢癌，仍然是最致命的妇科恶性肿瘤。由于其通常无症状或非特异性临床表现，约70% %的患者诊断为晚期（FIGO III-IV），典型特征为广泛的腹膜播散。尽管早期检测对改善生存结果至关重要，但目前的标准诊断方式，包括血清CA125和经阴道超声，缺乏足够的敏感性和特异性，无法在人群水平上筛查早期疾病。这篇综述全面评估了新兴的生物标志物和先进的诊断技术，特别关注液体活检分析，包括循环肿瘤DNA、microrna和子宫液体活检。我们进一步讨论了多生物标志物面板和人工智能（AI）驱动的模型的临床应用，这些模型集成了基因组、蛋白质组学和放射组学数据，同时强调了它们目前的性能局限性和阶段依赖的诊断准确性。尽管液体活检和基于人工智能的方法具有相当大的潜力，但与检测标准化和大规模前瞻性验证需求相关的挑战仍然是广泛临床实施的主要障碍。总的来说，本综述强调需要强有力的多模式诊断策略，以实现早期发现并最终降低oc相关死亡率。

{"title":"Recent advances in the early detection of ovarian cancer","authors":"Anahita Soleimani , Akbar Amirfiroozy , Mohammad M. Pourseif , Mahmoud Shekari Khaniani","doi":"10.1016/j.cca.2025.120797","DOIUrl":"10.1016/j.cca.2025.120797","url":null,"abstract":"<div><div>Ovarian cancer (OC), predominantly epithelial OC, remains the most lethal gynecological malignancy. Owing to its often asymptomatic or non-specific clinical presentation, approximately 70 % of patients are diagnosed at advanced stages (FIGO III–IV), typically characterized by extensive peritoneal dissemination. Although early detection is critical for improving survival outcomes, current standard diagnostic modalities, including serum CA125 and transvaginal ultrasound, lack sufficient sensitivity and specificity for population-level screening of early-stage disease. This review comprehensively evaluates emerging biomarkers and advanced diagnostic technologies, with a particular focus on liquid biopsy analytes, including circulating tumor DNA, microRNAs, and uterine liquid biopsies. We further discuss the clinical utility of multi-biomarker panels and artificial intelligence (AI)-driven models that integrate genomic, proteomic, and radiomic data, while highlighting their current performance limitations and stage-dependent diagnostic accuracy. Despite the considerable potential of liquid biopsies and AI-based approaches, challenges related to assay standardization and the need for large-scale prospective validation remain major barriers to widespread clinical implementation. Overall, this review underscores the need for robust, multimodal diagnostic strategies that may enable earlier detection and ultimately reduce OC-associated mortality.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"582 ","pages":"Article 120797"},"PeriodicalIF":2.9,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-invasive biological matrices on biosensor design 基于生物传感器设计的非侵入性生物基质。

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2026-02-15 Epub Date: 2025-12-11 DOI: 10.1016/j.cca.2025.120785

Ghada Al-Assi , Waleed K. Abdulsahib , Sanan Thaer Abdal-Wahab , G. Padma Priya , Subhashree Ray , Sindu Divakaran , Gunjan Mukherjee , Ashish Singh Chauhan , Gulsara Ruziyeva

A critical factor governing the performance and applicability of the point-of-care (POC) devices is the source of the sample matrix. This review article provides a comprehensive analysis of the various biological matrices utilized in POC biosensor development, evaluating their advantages, limitations, and potential. The traditional invasive sources such as blood offers a rich information profile but presents challenges for continuous monitoring. In contrast, this review emphasizes the growing focus on non-invasive and minimally invasive alternatives, including sweat, saliva, tears, urine, and nasal secretions. Each of these matrices presents a unique composition of biomarkers (e.g., electrolytes, metabolites, hormones, proteins) and distinct challenges related to sample collection, stability, and analyte concentration. The optical and electrochemical methods were utilized to examine these samples. We performed a comprehensive review of the development of POC devices in recent years and assessed their relative merits and drawbacks. Based on the progress of POC development, it illustrates that the various technological and economical requirements are urgent and tremendous. The tendency of high quality, low-cost POC devices, feature of biosensors (paper-based sensor, flexible device, microfluidic chip, et al.) currently widely used in POC and recommendations of future works were summarized.

控制点护理（POC）设备的性能和适用性的一个关键因素是样品矩阵的来源。本文综合分析了各种用于POC生物传感器开发的生物基质，评价了它们的优势、局限性和潜力。传统的侵入性来源如血液提供了丰富的信息概况，但对持续监测提出了挑战。相比之下，本综述强调越来越多的关注非侵入性和微创性替代方法，包括汗液、唾液、眼泪、尿液和鼻分泌物。每种基质都具有独特的生物标志物组成（如电解质、代谢物、激素、蛋白质），并且在样品收集、稳定性和分析物浓度方面存在不同的挑战。利用光学和电化学方法对这些样品进行了检测。我们对近年来POC器件的发展进行了全面的回顾，并评估了它们的相对优点和缺点。通过对POC发展进程的分析，说明了对POC的各种技术经济要求是迫切而巨大的。综述了高质量、低成本的POC器件的发展趋势，以及目前广泛应用于POC的生物传感器（纸质传感器、柔性器件、微流控芯片等）的特点和今后工作的建议。

{"title":"Non-invasive biological matrices on biosensor design","authors":"Ghada Al-Assi , Waleed K. Abdulsahib , Sanan Thaer Abdal-Wahab , G. Padma Priya , Subhashree Ray , Sindu Divakaran , Gunjan Mukherjee , Ashish Singh Chauhan , Gulsara Ruziyeva","doi":"10.1016/j.cca.2025.120785","DOIUrl":"10.1016/j.cca.2025.120785","url":null,"abstract":"<div><div>A critical factor governing the performance and applicability of the point-of-care (POC) devices is the source of the sample matrix. This review article provides a comprehensive analysis of the various biological matrices utilized in POC biosensor development, evaluating their advantages, limitations, and potential. The traditional invasive sources such as blood offers a rich information profile but presents challenges for continuous monitoring. In contrast, this review emphasizes the growing focus on non-invasive and minimally invasive alternatives, including sweat, saliva, tears, urine, and nasal secretions. Each of these matrices presents a unique composition of biomarkers (e.g., electrolytes, metabolites, hormones, proteins) and distinct challenges related to sample collection, stability, and analyte concentration. The optical and electrochemical methods were utilized to examine these samples. We performed a comprehensive review of the development of POC devices in recent years and assessed their relative merits and drawbacks. Based on the progress of POC development, it illustrates that the various technological and economical requirements are urgent and tremendous. The tendency of high quality, low-cost POC devices, feature of biosensors (paper-based sensor, flexible device, microfluidic chip, et al.) currently widely used in POC and recommendations of future works were summarized.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"582 ","pages":"Article 120785"},"PeriodicalIF":2.9,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can pharmacogenetics inform morphine dosing in the neonatal intensive care unit? A retrospective evaluation 药物遗传学可以告知新生儿重症监护病房吗啡的剂量吗？回顾性评价。

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2026-02-15 Epub Date: 2025-12-30 DOI: 10.1016/j.cca.2025.120814

Anastasiya Mankouski , Luca Brunelli , Gwendolyn McMillin

Acutely ill infants in the neonatal intensive care unit (NICU) present with complex medical conditions necessitating individualized therapeutic strategies. These infants exhibit significant variability in gestational age, birth weight, organ maturity and drug metabolism, increasing the risk of adverse drug reactions. Morphine is commonly prescribed in the NICU and is associated with a wide range of dosing as well as a high risk of adverse events. The objective of this retrospective study was to explore the potential relevance of pharmacogenomics to morphine dosing for our local level III NICU. Infants admitted between March and December 2022 were enrolled. Residual EDTA blood collected during routine clinical care was retrieved, and DNA was extracted for 55 patients. Targeted genotyping was performed to detect the rs1799971G > A variant of OPRM1 and the rs4680 G > A variant of COMT. Morphine dosing details were retrieved from medical records, and they were compared to genotypes. Median morphine oral equivalents per day (mg/kg) trended with OPRM1 genotype: AA, 0.0916 (n = 40); AG, 0.1500 (n = 13); GG, 0.2284 (n = 2). Median morphine oral equivalents and the number of days of treatment trended with COMT genotype: GG, 0.1429 mg/kg, 4 days (n = 17); AG, 0.1231 mg/kg, 6 days (n = 22); AA, 0.0875 mg/kg, 8 days (n = 15). Extremely premature infants required the highest morphine doses for the longest duration. Although statistical significance of these findings was not achieved, our data suggest that further studies are warranted to determine whether pharmacogenomics may be beneficial to individualize morphine dose requirements and improve outcomes for acutely ill infants in the NICU.

新生儿重症监护病房（NICU）的急性患儿目前具有复杂的医疗条件，需要个性化的治疗策略。这些婴儿在胎龄、出生体重、器官成熟度和药物代谢方面表现出显著的差异，增加了药物不良反应的风险。在新生儿重症监护室，吗啡是常用的处方药物，其剂量范围广，不良事件风险高。本回顾性研究的目的是探讨药物基因组学与我们当地III级新生儿重症监护室吗啡剂量的潜在相关性。在2022年3月至12月期间入学的婴儿被录取。收集临床常规护理中采集的EDTA残留血，提取55例患者的DNA。进行靶向基因分型检测rs1799971G > A型OPRM1变异和rs4680 G > A型COMT变异。从医疗记录中检索吗啡的剂量细节，并将其与基因型进行比较。每日吗啡口服当量中位数（mg/kg）随OPRM1基因型变化趋势：AA， 0.0916 (n = 40)；AG, 0.1500 (n = 13)；GG = 0.2284 （n = 2）。COMT基因型吗啡口服当量中位数和治疗天数趋势为：GG， 0.1429 mg/kg， 4 天（n = 17）；AG 0.1231 mg/kg， 6 天（n = 22）；AA, 0.0875 mg/kg， 8 天（n = 15）。极度早产儿需要最大剂量的吗啡，持续时间最长。虽然这些发现没有统计学意义，但我们的数据表明，需要进一步的研究来确定药物基因组学是否有利于个性化吗啡剂量需求和改善新生儿重症监护病房急性患儿的预后。

{"title":"Can pharmacogenetics inform morphine dosing in the neonatal intensive care unit? A retrospective evaluation","authors":"Anastasiya Mankouski , Luca Brunelli , Gwendolyn McMillin","doi":"10.1016/j.cca.2025.120814","DOIUrl":"10.1016/j.cca.2025.120814","url":null,"abstract":"<div><div>Acutely ill infants in the neonatal intensive care unit (NICU) present with complex medical conditions necessitating individualized therapeutic strategies. These infants exhibit significant variability in gestational age, birth weight, organ maturity and drug metabolism, increasing the risk of adverse drug reactions. Morphine is commonly prescribed in the NICU and is associated with a wide range of dosing as well as a high risk of adverse events. The objective of this retrospective study was to explore the potential relevance of pharmacogenomics to morphine dosing for our local level III NICU. Infants admitted between March and December 2022 were enrolled. Residual EDTA blood collected during routine clinical care was retrieved, and DNA was extracted for 55 patients. Targeted genotyping was performed to detect the rs1799971G > A variant of <em>OPRM1</em> and the rs4680 G > A variant of <em>COMT</em>. Morphine dosing details were retrieved from medical records, and they were compared to genotypes. Median morphine oral equivalents per day (mg/kg) trended with <em>OPRM1</em> genotype: AA, 0.0916 (<em>n</em> = 40); AG, 0.1500 (<em>n</em> = 13); GG, 0.2284 (<em>n</em> = 2). Median morphine oral equivalents and the number of days of treatment trended with <em>COMT</em> genotype: GG, 0.1429 mg/kg, 4 days (<em>n</em> = 17); AG, 0.1231 mg/kg, 6 days (<em>n</em> = 22); AA, 0.0875 mg/kg, 8 days (<em>n</em> = 15). Extremely premature infants required the highest morphine doses for the longest duration. Although statistical significance of these findings was not achieved, our data suggest that further studies are warranted to determine whether pharmacogenomics may be beneficial to individualize morphine dose requirements and improve outcomes for acutely ill infants in the NICU.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"582 ","pages":"Article 120814"},"PeriodicalIF":2.9,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Professor Alan H.B. Wu: Contributions that will stand the test of time 吴浩斌教授：经得起时间考验的贡献。

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2026-02-15 Epub Date: 2025-12-18 DOI: 10.1016/j.cca.2025.120795

Robert H. Christenson , Pete Kavsak , Xander M.R. van Wijk

This article honors Dr. Alan H.B. Wu's 25-year leadership as Editor-in-Chief of Clinica Chimica Acta and his transformative contributions to clinical chemistry and laboratory medicine. A central focus of his career has been advancing the use of cardiac biomarkers, particularly cardiac troponin (cTn) and natriuretic peptides, for the diagnosis and management of myocardial infarction and heart failure. Dr. Wu's studies helped establish the diagnostic and prognostic value of cTn, contributed to standardization and high-sensitivity assay development, and explored novel technologies. His work on biological variability emphasized the limitations of population-based reference intervals and promoted individualized interpretation of test results. Through guidelines and collaborations, Dr. Wu has shaped biomarker adoption, clinical practice, and laboratory quality standards. His vision of personalized laboratory medicine continues to advance diagnostics and improve patient care.

这篇文章是为了纪念Alan H.B. Wu博士25年来作为《临床化学学报》总编辑的领导地位，以及他对临床化学和实验室医学的变革性贡献。他职业生涯的中心焦点一直是推进心脏生物标志物的使用，特别是心肌肌钙蛋白（cTn）和利钠肽，用于心肌梗死和心力衰竭的诊断和管理。吴博士的研究帮助建立了cTn的诊断和预后价值，促进了标准化和高灵敏度检测的发展，并探索了新技术。他在生物变异方面的工作强调了基于人群的参考区间的局限性，并促进了对测试结果的个性化解释。通过指导和合作，吴博士塑造了生物标志物的采用、临床实践和实验室质量标准。他对个性化实验室医学的愿景继续推进诊断和改善患者护理。

引用次数: 0

Aberrantly glycosylated PSMA in urine as a potential marker for prostate cancer 尿中PSMA异常糖基化作为前列腺癌的潜在标志物。

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta

Pub Date : 2026-02-15 Epub Date: 2025-12-20 DOI: 10.1016/j.cca.2025.120790

Misba Khan , Md. Khirul Islam , Pekka Taimen , Peter J. Boström , Urpo Lamminmäki , Janne Leivo

Early detection of prostate cancer (PCa) requires the development of reliable non-invasive biomarkers. In this study, we describe a simple, non-invasive assay to detect a prostate-specific membrane antigen (PSMA) glycoisoform directly from unprocessed urine. PSMA was analyzed in urine samples from PCa patients (n = 40) and benign controls (n = 37) using lectin MGL-coated europium-doped nanoparticles. MGL showed enhanced binding to PCa-derived PSMA, indicating aberrant glycosylation. Evaluation of individual samples demonstrated that the PSMA-MGL glycovariant assay significantly discriminated PCa from benign conditions (p = 0.01 pilot, p = 0.02 validation). Moreover, this assay exhibited a three-fold improvement in sensitivity over conventional antibody-based PSMA detection. ROC analysis showed an AUC of 0.648 for PSMA-MGL, which increased to 0.734 when combined with free-PSA and urinary creatinine, highlighting the enhanced diagnostic potential of this multimarker, non-invasive approach.

前列腺癌（PCa）的早期检测需要开发可靠的非侵入性生物标志物。在这项研究中，我们描述了一种简单的，非侵入性的检测方法，可以直接从未经处理的尿液中检测前列腺特异性膜抗原（PSMA）糖异构体。采用凝集素mgl包被的掺铕纳米颗粒对PCa患者（n = 40）和良性对照（n = 37）的尿液样本进行PSMA分析。MGL与ca来源的PSMA结合增强，表明异常糖基化。个体样本的评估表明，PSMA-MGL糖变异体检测能显著区分PCa与良性病变（p = 0.01先导验证，p = 0.02验证）。此外，与传统的基于抗体的PSMA检测相比，该检测的灵敏度提高了三倍。ROC分析显示，PSMA-MGL的AUC为0.648，与游离psa和尿肌酐联合使用时AUC增加至0.734，突出了这种多标记、无创入路的诊断潜力。

引用次数: 0